Associate Professor
Email:xiaozhu@fudan.edu.cnDr Zhu is an Associate Professor in Pharmacometricssince 2021. In 2012, he graduated with a bachelor’s degree in Pharmaceutical Science from Fudan University. He obtained a master’s degree in Pharmacy from the Chinese University of Hong Kong in 2015 and a PhD in Pharmacometrics from University of Otago in 2019 under the supervision of Prof. Stephen Duffull and Prof. Michelle Glass. During 2019-2020 he was supported by a grant from Murdoch Children's Research Institute as a postdoc research fellow at the University of Otago. His current research involves the development of pharmacological models, population analysis of pharmacokinetic (PK) and pharmacodynamic (PD) data, and the optimal design of clinical studies. He has developed population PK/PD models in a range of therapeutic areas, primarily for oncology, bacterial infections, and neuroscience. His research facilitates the translation of drug effects from preclinical (in vitro and in vivo) to patients and from early to late clinical development, and for optimising clinical usage of drugs.
Population pharmacokinetics and pharmacodynamics
Receptor theory
Therapeutic drug monitoring
Optimal study design
Education
University of Otago
Mar 2016 –May 2019 Ph.D.in Pharmacometrics
Supervisor: Prof. Stephen Duffull, Prof. Michelle Glass
The Chinese University of Hong Kong
Aug 2012 –Sep 2015 M.Phil.in Pharmacy
Supervisor: Prof. Tai-ning Lam, Prof. Zhong Zuo
Peking University/Pfizer Pharmacometrics Education Center
Feb 2015 –July 2015 Exchange Student
Supervisor: Prof. Wei Lu, Prof. Tian-yan Zhou
Fudan University
Sept2008 –July 2012 B.Sc. in Pharmaceutical Science
ProfessionalExperiences
July 2021 – Present Associate Professor of Pharmacometrics at Fudan University
Mar 2020 – June 2021 Honorary Fellow in Murdoch Children's Research Institute
Nov 2019 – Dec 2020 Postdoctoral Fellow (Pharmacometrics) in Otago Pharmacometrics Group
Jun 2019 – Oct 2019 Assistant Research Fellow (Pharmacometrics) in Otago Pharmacometrics Group
TeachingActivities
Nov 2019 Lecturer
Workshop: The beginners’ course for NONMEM
Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists - Population Approach Group of Australia & New Zealand (ASCEPT-PAGANZ) 2019 Joint Scientific Meeting, Queenstown, New Zealand.
Jan 2017 Lecturer
Workshop: Multi-state receptor theory and “biased” ligands
PAGANZ Meeting 2017, Adelaide, Australia
Grants& Projects
Project1. Application of pharmacometric methods to quantify functional selectivity
Project2: The vancomycin cohort study – assessing precise dosing and prompt drug monitoring to
improve attainment of target concentrations
Awards & Honors
2020 Chinese government award for outstanding self-financed students abroadby the China Scholarship Council
2019 ASCEPT New Zealand Fred Fastier Prize
2019 ASCEPT and PAGANZ Student Travel Grants
2019 International Society of Pharmacometrics (ISoP) Student Prize for pharmacometrics, PAGANZ Meeting 2019, Auckland, New Zealand
Title: Evaluation of the fingerprint profiles of the cannabinoid-1 receptor signalling via a kinetic modelling approach
2019 Best Research Paper of Year 2018 at School of Pharmacy, University of Otago
Title: An evaluation of the operational model when applied to quantify functional selectivity
Selected Publications（latest 5 yrs，<20papers）
1.Brusamarello C, Daley AJ, Zhu X, Landersdorfer C, Gwee A. (2021). How important are MIC determination methods when targeting vancomycin levels in patients with Staphylococcus aureus infections? J Antimicrob Chemotherhttps://doi.org/10.1093/jac/dkab065
2.Li ZR, Wang CY, Zhu X, Jiao Z. (2021). Population Pharmacokinetics of Levetiracetam: A Systematic Review. Clin Pharmacokinet 60: 305–318.
3.Gwee A, Duffull SB, Zhu X, Tong SY, Cranswick N, McWhinney B, Ungerer J, Francis J, Steer AC. (2020). Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children. PLoS neglected tropical diseases 14(12), e0008886.
4.Zhu X*, Finlay DB, Glass M, Duffull SB (2020). Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling. Br J Pharmacol https://doi.org/10.1111/bph.15066
5.Ji XW, Xue F, Kang ZS, Zhong W, Hui-san Kuan I, Yang XP, Zhu X*, et al. (2020). Model-informed drug development of benapenem: Pharmacokinetic/Pharmacodynamic cutoff value determination and antibacterial efficacy against enterobacteriaceae. Antimicrob Agents Chemother 64(3), pii: e01751-19. (Co-corresponding author)
6.Wang S#, Zhu X#, Han M, Hao F, Lu W, Zhou T. (2020). Mechanistic Pharmacokinetic/Pharmacodynamic Model of Sunitinib and Dopamine in MCF-7/Adr Xenografts: Linking Cellular Heterogeneity to Tumour Burden. AAPS J 22(2), 45. (Co-first author)
7.Kuan IHS, Wright DFB, Duffull SB, Zhu X*. (2020). Understanding the association between metformin plasma concentrations and lactate. Br J Clin Pharmacol. doi:10.1111/bcp.14394 (Corresponding author)
8.Peña‐Silva R, Duffull, SB, Steer AC, Jaramillo‐Rincon SX, Gwee A, Zhu X*. (2020). Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID‐19. Br J Clin Pharmacol. doi.org/10.1111/bcp.14476 (Corresponding author)
9.Yang L, Yong L, Zhu X, Feng Y, Fu Y, Kong D, Lu W, Zhou TY. (2020). Disease progression model of 4T1 metastatic breast cancer. J Pharmacokinet and Pharmacodyn, 47(1), 105-116.
10.Zhu X#, Finlay DB#, Glass M, Duffull SB (2019). Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors. Br J Pharmacol 14:2593-2607 (Co-first author)
11.Zhu X*, Finlay DB, Glass M, Duffull SB (2019). An intact model for quantifying functional selectivity. Sci. Rep9(1), 2557
12.Liu Z, Galettis P, Broyd SJ, van Hell H, Greenwood LM, de Krey P, Steigler A, Zhu X, et al. (2019). Model-based analysis on systemic availability of coadministered cannabinoids after controlled vaporised administration. Intern Med J doi: 10.1111/imj.14415.
13.Zhu X*, Finlay DB, Glass M, Duffull SB (2018). An evaluation of the operational model when applied to quantify functional selectivity. Br J Pharmacol 10: 1654-1668
14.Ji XW, Ji SM, He XR, Zhu X, Chen R, Lu W (2018). Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients. Acta Pharmacol Sin 39: 286-293.
15.Deng J, Jhandey A, Zhu X, Yang Z, Yik KFP, Zuo Z, Lam TN (2018). In silico drug absorption tract: An agent-based biomimetic model for human oral drug absorption. PloS one 13(8), e0203361.
16.Chen YS, Liu ZQ, Chen R, Wang L, Huang L, Zhu X, et al. (2017). Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients. Acta Pharmacol Sin 38: 1195-1204.
17.Deng J, Zhu X, Chen Z, Fan CH, Kwan HS, Wong CH, Shek KY, Zuo Z, Lam TN (2017). A Review of Food-Drug Interactions on Oral Drug Absorption. Drugs 77:1833-1855
18.Hao F, Wang S, Zhu X, Xue J, Li J, Wang L, et al. (2017). Pharmacokinetic-Pharmacodynamic Modeling of the Anti-Tumor Effect of Sunitinib Combined with Dopamine in the Human Non-Small Cell Lung Cancer Xenograft. Pharm Res 34: 408-418.
19.Zhu X, Deng J, Zuo Z, Lam TN (2016). An Agent-Based Approach to Dynamically Represent the Pharmacokinetic Properties of Baicalein. AAPS J 18: 1475-1488.
20.Ji XW, Ji SM, Li RT, Wu KH, Zhu X, Lu W, et al. (2016). Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice. Acta Pharmacol Sin 37: 825-833.
